AstraZeneca, Ranbaxy Can't Ax Claims In Nexium Antitrust MDL

Law360, Los Angeles (November 27, 2013, 10:13 PM ET) -- A Massachusetts federal judge on Wednesday rejected AstraZeneca PLC and Ranbaxy Inc.'s bid to dismiss as time-barred certain claims in multidistrict litigation alleging the companies violated antitrust laws by agreeing to delay entry of a generic version of AstraZeneca’s heartburn drug Nexium.

U.S. District Judge William G. Young denied AstraZeneca and generics manufacturer Ranbaxy's motion for partial summary judgment on claims relating to Ranbaxy's alleged exclusion from the market because of a settlement agreement between the two companies, saying the plaintiffs have presented evidence supporting their...
To view the full article, register now.